Vas-01 is under clinical development by VasGene Therapeutics and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According to GlobalData, Phase II drugs for Metastatic Transitional (Urothelial) Tract Cancer have a 46% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vas-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vas-01 overview

Vas-01 (Recombinant fusion protein) is under development for the treatment of metastatic castration-resistant prostate cancer, Kaposi sarcoma and metastatic or recurrent solid tumors, metastatic urothelial carcinoma, non-small cell lung cancer, refractory bladder cancer, pancreatic cancer, colorectal cancer, head and neck cancer squamous cell carcinomas like hypopharyngeal carcinoma, laryngeal cancer, lip and oral cavity cancer, oropharyngeal carcinoma, malignant pleural mesothelioma, bile duct cancer (cholangiocarcinoma), gall bladder cancer and hepatocellular carcinoma. The drug is administered intravenously and intravesically. The recombinant fusion protein is composed of the full-length extracellular domain (soluble) of human receptor tyrosine kinase ephrin type-B receptor 4 (sEphB4) and fused, at its C-terminus, to full-length human serum albumin (HSA).

The drug was also under development for relapsed or refractory myelodysplastic syndrome and acute myeloid leukemia.

VasGene Therapeutics overview

VasGene Therapeutics (VasGene) is a biotechnology company that discovers, develops and commercializes therapeutics based on the understanding of vascular biology and cancer biology. The company offers pipeline products such as soluble therapeutic proteins, therapeutic monoclonal antibodies and anti-drug conjugates. VasGene’s products are used in the treatment of cancer, AMD, and diabetic eye. It markets its products through its network of distributors across the world. The company provides the foundation for new, rational, and technologically sophisticated approaches to cancer therapeutics. VasGene is headquartered in Los Angeles, California, the US.

For a complete picture of Vas-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.